Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMACNASDAQ:INMNASDAQ:PALINASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMACIMAC$0.03+6.1%$0.09$0.75▼$1.65$874K-0.88708,132 shs8,322 shsINMInMed Pharmaceuticals$2.76+0.4%$2.66$1.72▼$15.70$3.33M0.21244,785 shs41,249 shsPALIPalisade Bio$0.81+6.7%$0.72$0.60▼$5.38$3.87M1.46515,875 shs87,534 shsSPRCSciSparc$0.31-0.8%$0.30$0.20▼$1.79$3.33M0.754.16 million shs285,254 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMACIMAC+6.11%-9.84%-25.00%-94.97%-98.94%INMInMed Pharmaceuticals+0.36%-6.44%-6.44%-11.54%-60.45%PALIPalisade Bio+6.68%+17.50%+14.05%-14.44%-84.36%SPRCSciSparc-0.81%-2.66%+7.14%-31.05%-73.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMACIMACN/AN/AN/AN/AN/AN/AN/AN/AINMInMed Pharmaceuticals0.4165 of 5 stars0.05.00.00.00.00.00.6PALIPalisade Bio2.9478 of 5 stars3.55.00.00.02.60.01.3SPRCSciSparc0.659 of 5 stars0.05.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMACIMAC 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/APALIPalisade Bio 3.00Buy$12.001,386.99% UpsideSPRCSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMAC, INM, PALI, and SPRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMACIMAC$15.22M0.06N/AN/A$0.69 per share0.05INMInMed Pharmaceuticals$4.83M0.69N/AN/A$5.12 per share0.54PALIPalisade Bio$250K15.48N/AN/A$18.29 per share0.04SPRCSciSparc$1.31M2.55N/AN/A$13.57 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-163.75%-90.74%-71.70%N/APALIPalisade Bio-$12.30M-$6.80N/AN/AN/AN/A-148.51%-115.16%8/11/2025 (Estimated)SPRCSciSparc-$5.12MN/A0.00∞N/AN/AN/AN/AN/ALatest IMAC, INM, PALI, and SPRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 million5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/A3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMACIMACN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMACIMAC0.011.271.27INMInMed Pharmaceuticals0.093.052.44PALIPalisade BioN/A3.313.31SPRCSciSparcN/A1.861.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMACIMAC24.27%INMInMed Pharmaceuticals20.12%PALIPalisade Bio11.79%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipIMACIMAC10.00%INMInMed Pharmaceuticals1.85%PALIPalisade Bio3.28%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMACIMAC10626.49 million23.84 millionNot OptionableINMInMed Pharmaceuticals101.21 million711,000Not OptionablePALIPalisade Bio104.80 million2.68 millionNot OptionableSPRCSciSparc410.83 million10.20 millionNot OptionableIMAC, INM, PALI, and SPRC HeadlinesRecent News About These CompaniesSciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.May 13, 2025 | nasdaq.comSciSparc and Clearmind Secure European Patent for Cocaine Addiction TherapyMay 13, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine AddictionMay 12, 2025 | uk.finance.yahoo.comSciSparc announces collaboration with Clearmind MedicineApril 26, 2025 | markets.businessinsider.comScisparc and Clearmind Push into Eating Disorder And Addiction Treatment With New PatentsApril 25, 2025 | theglobeandmail.comSciSparc and Clearmind File Patent for Eating Disorder TreatmentApril 25, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | globenewswire.comSciSparc Extends Deadline for Miza III Ventures DealApril 1, 2025 | tipranks.comSciSparc Ltd. Extends Merger Agreement with AutoMax MotorsApril 1, 2025 | tipranks.comSciSparc files to sell 61.21M ordinary shares for holdersMarch 26, 2025 | markets.businessinsider.comSciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent ApplicationMarch 11, 2025 | tipranks.comClearmind Medicine Inc.: Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South KoreaMarch 10, 2025 | finanznachrichten.deSciSparc announces publication of patent via Clearmind collaborationMarch 10, 2025 | markets.businessinsider.comSciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine AddictionMarch 10, 2025 | quiverquant.comSciSparc Ltd. Agrees to Sell MitoCareX to N2OFFMarch 3, 2025 | tipranks.comSciSparc Ltd: SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant CancersMarch 3, 2025 | finanznachrichten.deSciSparc signs definitive agreement to sell MitoCareX to N2OFFMarch 3, 2025 | markets.businessinsider.comSciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange AgreementMarch 3, 2025 | quiverquant.comSciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant CancersMarch 3, 2025 | globenewswire.comSciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric VehiclesFebruary 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumThese 3 Rock Star Entertainment Stocks Are Dominating 2025By Leo Miller | May 7, 2025View These 3 Rock Star Entertainment Stocks Are Dominating 2025Why Flutter Entertainment May Be a Resilient Sports Betting StockBy Chris Markoch | May 9, 2025View Why Flutter Entertainment May Be a Resilient Sports Betting StockIMAC, INM, PALI, and SPRC Company DescriptionsIMAC NASDAQ:IMAC$0.03 +0.00 (+6.11%) As of 05/22/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.InMed Pharmaceuticals NASDAQ:INM$2.76 +0.01 (+0.36%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.84 +0.08 (+2.90%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Palisade Bio NASDAQ:PALI$0.81 +0.05 (+6.68%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.80 -0.01 (-1.49%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.SciSparc NASDAQ:SPRC$0.31 0.00 (-0.81%) Closing price 05/23/2025 03:54 PM EasternExtended Trading$0.30 0.00 (-1.46%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
